氯氮平用于治疗伴有精神病性症状的心境障碍、精神分裂症伴情感症状及精神分裂症。
Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia.
作者信息
McElroy S L, Dessain E C, Pope H G, Cole J O, Keck P E, Frankenberg F R, Aizley H G, O'Brien S
机构信息
Biological Psychiatry Program, University of Cincinnati College of Medicine, OH 45267-0559.
出版信息
J Clin Psychiatry. 1991 Oct;52(10):411-4.
BACKGROUND
Although growing research indicates that the atypical antipsychotic agent clozapine is effective in patients with schizophrenia, little is known about the efficacy of clozapine in patients with schizoaffective disorder or psychotic mood disorders. The purpose of this study was to assess whether or not clozapine is effective in some patients with schizoaffective disorder or psychotic mood disorders.
METHOD
By surveying treating clinicians and chart data, we assessed treatment response in 85 consecutive patients, including 39 with schizophrenia, 25 with schizoaffective disorder, and 14 with bipolar disorder with psychotic features, who received clozapine for at least 6 weeks at our center.
RESULTS
All patients were either inadequately responsive to or unable to tolerate standard somatic therapies. Compared to patients with schizophrenia, patients with schizoaffective disorder and bipolar disorder with psychotic features displayed significantly higher response rates to clozapine.
CONCLUSION
Clozapine may be a useful drug in the treatment of patients with schizoaffective disorder or psychotic mood disorders who are treatment resistant or intolerant of side effects.
背景
尽管越来越多的研究表明非典型抗精神病药物氯氮平对精神分裂症患者有效，但对于氯氮平在分裂情感性障碍或伴有精神病性症状的心境障碍患者中的疗效知之甚少。本研究的目的是评估氯氮平对某些分裂情感性障碍或伴有精神病性症状的心境障碍患者是否有效。
方法
通过调查治疗医生和病历数据，我们评估了85例连续患者的治疗反应，其中包括39例精神分裂症患者、25例分裂情感性障碍患者和14例伴有精神病性症状的双相情感障碍患者，这些患者在我们中心接受了至少6周的氯氮平治疗。
结果
所有患者对标准躯体治疗反应不佳或无法耐受。与精神分裂症患者相比，分裂情感性障碍患者和伴有精神病性症状的双相情感障碍患者对氯氮平的反应率显著更高。
结论
氯氮平可能是治疗对治疗耐药或不耐受副作用的分裂情感性障碍或伴有精神病性症状的心境障碍患者的一种有用药物。
Zotero 插件